Form 4: Monopar Therapeutics Executive Granted Stock Options

Patrice Rioux, Acting Chief Medical Officer of Monopar Therapeutics, was granted 2,000 stock options on January 1, 2025.

Summary

• Patrice Rioux, the Acting Chief Medical Officer of Monopar Therapeutics, was granted 2,000 stock options.
• The options have an exercise price of $22.
• The options vest monthly, starting with 1/12th of the options on January 31, 2025, and continuing each month-end thereafter.
• The options expire on December 31, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of executive compensation, which is generally viewed positively as it aligns management and shareholder interests. There are no negative implications.

Positives

• The grant of stock options aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to incentivize performance and align management interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard practice for incentivizing executives in the biotech industry.
• The vesting schedule of 1/12th per month is a common approach to encourage long-term commitment.
• The exercise price of $22 is specific to Monopar Therapeutics and would need to be compared to the current market price of the stock to assess its value.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the executive to increase the company's value.
• The executive benefits from the potential future value of the stock options.

Key Dates

Keywords

stock options, executive compensation, insider trading, Monopar Therapeutics, MNPR, Patrice Rioux